Parkinson's disease: Autoimmunity and neuroinflammation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Parkinson, 1817
Sylvius de la Boë, 1680, Opera Medica
Tyler, 1992, A history of Parkinson's disease, 1
Manyam, 1999, Traditional and complementary therapies in Parkinson's disease, Adv Neurol, 80, 565
Zhang, 2006, Early descriptions of Parkinson's disease in ancient China, Arch Neurol, 63, 782, 10.1001/archneur.63.5.782
Charcot, 1877, On Parkinson's disease, 129
Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03
Alzheimer's Association, 2014, 2014 Alzheimer's disease facts and figures, Alzheimers Dement, 10, e47, 10.1016/j.jalz.2014.02.001
Van Den Eeden, 2003, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity, Am J Epidemiol, 157, 1015, 10.1093/aje/kwg068
De Lau, 2006, Epidemiology of Parkinson's disease, Lancet Neurol, 5, 525, 10.1016/S1474-4422(06)70471-9
Driver, 2009, Incidence and remaining lifetime risk of Parkinson disease in advanced age, Neurology, 72, 432, 10.1212/01.wnl.0000341769.50075.bb
Pringsheim, 2014, The prevalence of Parkinson's disease: a systematic review and meta-analysis, Mov Disord, 29, 1583, 10.1002/mds.25945
Lesage, 2009, Parkinson's disease: from monogenic forms to genetic susceptibility factors, Hum Mol Genet, 18, R48, 10.1093/hmg/ddp012
Rosner, 2008, Advances in the genetics of Parkinson's disease, Acta Pharmacol Sin, 29, 21, 10.1111/j.1745-7254.2008.00731.x
Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann Neurol, 72, 893, 10.1002/ana.23687
Benkler, 2009, Parkinson's disease, autoimmunity, and olfaction, Int J Neurosci, 119, 2133, 10.3109/00207450903178786
Møller, 1989, Parkinson's disease and autoimmunity, Acta Neurol Scand, 79, 173, 10.1111/j.1600-0404.1989.tb03733.x
Liu, 2003, Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injury: role of neuroinflammation, Environ Health Perspect, 111, 1065, 10.1289/ehp.6361
Fiszer, 1994, Gamma delta+T cells are increased in patients with Parkinson's disease, J Neurol Sci, 121, 39, 10.1016/0022-510X(94)90154-6
Benkler, 2012, Immunology, autoimmunity, and autoantibodies in Parkinson's disease, Clin Rev Allergy Immunol, 42, 164, 10.1007/s12016-010-8242-y
Double, 2009, Anti-melanin antibodies are increased in sera in Parkinson's disease, Exp Neurol, 217, 297, 10.1016/j.expneurol.2009.03.002
Papachroni, 2007, Autoantibodies to alpha-synuclein in inherited Parkinson's disease, J Neurochem, 101, 749, 10.1111/j.1471-4159.2006.04365.x
Yanamandra, 2011, Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients, PLoS One, 6, e18513, 10.1371/journal.pone.0018513
Zappia, 2002, Anti-GM1 ganglioside antibodies in Parkinson's disease, Acta Neurol Scand, 106, 54, 10.1034/j.1600-0404.2002.01240.x
Orr, 2005, A possible role for humoral immunity in the pathogenesis of Parkinson's disease, Brain, 128, 2665, 10.1093/brain/awh625
Graham, 1979, On the origin and significance of neuromelanin, Arch Pathol Lab Med, 103, 359
Oberlander, 2011, Neuromelanin is an immune stimulator for dendritic cells in vitro, BMC Neurosci, 12, 116, 10.1186/1471-2202-12-116
Koutsilieri, 2013, Autoimmunity, dendritic cells and relevance for Parkinson's disease, J Neural Transm, 120, 75, 10.1007/s00702-012-0842-7
Wilms, 2003, Activation of microglia by human neuromelanin is NFkappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease, FASEB J, 17, 500, 10.1096/fj.02-0314fje
Zhang, 2011, Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease, Neurotox Res, 19, 63, 10.1007/s12640-009-9140-z
Carvey, 1991, The potential use of dopamine neuron antibody and a striatal-derived neurotropic factor as diagnostic markers in Parkinson's disease, Neurology, 41, 53, 10.1212/WNL.41.5_Suppl_2.53
Le, 1999, Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells, Arch Neurol, 56, 194, 10.1001/archneur.56.2.194
Chen, 1998, Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins, Arch Neurol, 55, 1075, 10.1001/archneur.55.8.1075
He, 2002, Role of FCγ receptors in nigral cell injury induced by Parkinson's disease immunoglobulin injection into mouse substantia nigra, Exp Neurol, 176, 322, 10.1006/exnr.2002.7946
Abramsky, 1978, Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia, Perspect Biol Med, 22, 104114
Luedtke, 1999, Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes, J Neuroimmunol, 101, 170, 10.1016/S0165-5728(99)00142-3
Myers, 1976, Evidence for a dopamine receptor antibody, Biochem Biophys Res Commun, 72, 1311, 10.1016/S0006-291X(76)80158-1
Farooqui, 1991, Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum, J Neurochem, 57, 1363, 10.1111/j.1471-4159.1991.tb08302.x
Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745
Postuma, 2012, Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease, Mov Disord, 27, 617, 10.1002/mds.24996
Hely, 2005, Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15years, Mov Disord, 20, 190, 10.1002/mds.20324
Hely, 2008, The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20years, Mov Disord, 23, 837, 10.1002/mds.21956
Lerler, 2008, Olfactory pathogenesis of idiopathic Parkinson disease revisited, Mov Disord, 23, 1076, 10.1002/mds.22066
Iwanaga, 1999, Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases, Neurology, 52, 1269, 10.1212/WNL.52.6.1269
Goetz, 2011, The history of Parkinson's disease: early clinical descriptions and neurological therapies, Cold Spring Harb Perspect Med, 1, a008862, 10.1101/cshperspect.a008862
Popat, 2011, Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease, Eur J Neurol, 18, 756, 10.1111/j.1468-1331.2011.03353.x
Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008
Parnetti, 2013, Cerebrospinal fluid biomarkers in Parkinson disease, Nat Rev Neurol, 9, 131, 10.1038/nrneurol.2013.10
Brooks, 2011, Imaging biomarkers in Parkinson's disease, Prog Neurobiol, 95, 614, 10.1016/j.pneurobio.2011.08.009
Lehericy, 2012, Magnetic resonance imaging of the substantia nigra in Parkinson's disease, Mov Disord, 27, 822, 10.1002/mds.25015
Lehericy, 2014, 7 tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease, Mov Disord, 29, 1574, 10.1002/mds.26043
Fox, 2011, The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease, Mov Disord, 26, S2, 10.1002/mds.23829
Connolly, 2014, Pharmacological treatment of Parkinson's disease: a review, JAMA, 311, 1670, 10.1001/jama.2014.3654
Ton, 2006, Non steroidal anti-inflammatory drugs and risk of Parkinson's disease, Mov Disord, 21, 964, 10.1002/mds.20856
Plane, 2010, Prospects for minocycline neuroprotection, Arch Neurol, 67, 1442, 10.1001/archneurol.2010.191
Ravina, 2006, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease, Neurology, 66, 664, 10.1212/01.wnl.0000201252.57661.e1
Thevenet, 2011, Regulation of LRRK2 expression points to a functional role in human monocyte maturation, PLoS One, 6, e21519, 10.1371/journal.pone.0021519
Moehle, 2012, LRRK2 inhibition attenuates microglial inflammatory responses, J Neurosci, 32, 1602, 10.1523/JNEUROSCI.5601-11.2012
Wenz, 2009, PGC-1α activation as a therapeutic approach in mitochondrial disease, IUBMB Life, 61, 1051, 10.1002/iub.261
Hondares, 2007, PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle, Biochem Biophys Res Commun, 354, 1021, 10.1016/j.bbrc.2007.01.092
Pardo, 2011, Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator- activated receptor γ coactivator-1α, PLoS One, 6, e26989, 10.1371/journal.pone.0026989
Suwa, 2006, Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo, J Appl Physiol, 101, 1685, 10.1152/japplphysiol.00255.2006
Chowanadisai, 2010, Pyrroloquinoline quinine stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression, J Biol Chem, 285, 142, 10.1074/jbc.M109.030130
Irrcher, 2008, AMP activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells, PLoS One, 3, e3614, 10.1371/journal.pone.0003614
Lagouge, 2006, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, 127, 1109, 10.1016/j.cell.2006.11.013
Shoenfeld, 2008, The mosaic of autoimmunity: prediction, autoantibodies and therapy in autoimmune disease, IMAJ, 10, 13